Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45

Benzinga · 1d ago
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $42 to $45.